Autolus Therapeutics plc Files 2023 Annual Report on Form 10-K

Ticker: AUTL · Form: 10-K · Filed: Mar 21, 2024 · CIK: 1730463

Autolus Therapeutics PLC 10-K Filing Summary
FieldDetail
CompanyAutolus Therapeutics PLC (AUTL)
Form Type10-K
Filed DateMar 21, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.000042, $2.38
Sentimentneutral

Sentiment: neutral

Topics: Autolus Therapeutics, 10-K, Biotechnology, Annual Report, Financials

TL;DR

<b>Autolus Therapeutics plc has filed its 2023 Form 10-K, detailing its financial performance and corporate information for the fiscal year ending December 31, 2023.</b>

AI Summary

Autolus Therapeutics plc (AUTL) filed a Annual Report (10-K) with the SEC on March 21, 2024. Autolus Therapeutics plc filed its 2023 Annual Report on Form 10-K on March 21, 2024. The report covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at The Mediaworks, 191 Wood Lane, London, W12 7FP. Autolus Therapeutics plc was formerly known as Autolus Therapeutics Ltd, with a name change effective February 5, 2018. The filing includes details on ordinary shares and deferred class shares (A, B, C) for various fiscal periods.

Why It Matters

For investors and stakeholders tracking Autolus Therapeutics plc, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Autolus Therapeutics' financial health, operational status, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's progress and future prospects. The detailed financial statements and disclosures within the 10-K are essential for understanding the company's financial position, including its share structure and capital accounts, enabling informed investment decisions.

Risk Assessment

Risk Level: medium — Autolus Therapeutics plc shows moderate risk based on this filing. The company is in the biotechnology sector, which is inherently high-risk due to long development cycles, regulatory hurdles, and clinical trial outcomes. Specific financial data like revenue and net income are not yet available in this header-level data, indicating it's likely an early-stage or pre-revenue company, increasing financial risk.

Analyst Insight

Review the full 10-K filing to understand Autolus Therapeutics' financial performance, clinical trial progress, and strategic outlook for 2023, paying close attention to revenue generation, cash burn, and upcoming milestones.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Period of report)
  • 2024-03-21 — Filing Date (Date the 10-K was filed)
  • 2018-02-05 — Name Change Date (Date Autolus Therapeutics plc was formerly known as Autolus Therapeutics Ltd)

Key Players & Entities

  • Autolus Therapeutics plc (company) — Filer name
  • Autolus Therapeutics Ltd (company) — Former company name
  • The Mediaworks (company) — Business address street 1
  • 191 Wood Lane (company) — Business address street 2
  • London (company) — Business address city
  • W12 7FP (company) — Business address zip

FAQ

When did Autolus Therapeutics plc file this 10-K?

Autolus Therapeutics plc filed this Annual Report (10-K) with the SEC on March 21, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Autolus Therapeutics plc (AUTL).

Where can I read the original 10-K filing from Autolus Therapeutics plc?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Autolus Therapeutics plc.

What are the key takeaways from Autolus Therapeutics plc's 10-K?

Autolus Therapeutics plc filed this 10-K on March 21, 2024. Key takeaways: Autolus Therapeutics plc filed its 2023 Annual Report on Form 10-K on March 21, 2024.. The report covers the fiscal year ending December 31, 2023.. The company's principal executive offices are located at The Mediaworks, 191 Wood Lane, London, W12 7FP..

Is Autolus Therapeutics plc a risky investment based on this filing?

Based on this 10-K, Autolus Therapeutics plc presents a moderate-risk profile. The company is in the biotechnology sector, which is inherently high-risk due to long development cycles, regulatory hurdles, and clinical trial outcomes. Specific financial data like revenue and net income are not yet available in this header-level data, indicating it's likely an early-stage or pre-revenue company, increasing financial risk.

What should investors do after reading Autolus Therapeutics plc's 10-K?

Review the full 10-K filing to understand Autolus Therapeutics' financial performance, clinical trial progress, and strategic outlook for 2023, paying close attention to revenue generation, cash burn, and upcoming milestones. The overall sentiment from this filing is neutral.

Risk Factors

  • Financial Resources and Liquidity [high — financial]: The company's ability to fund its operations and development programs depends on its access to capital, which is subject to market conditions and investor sentiment.
  • Regulatory Approval Process [high — regulatory]: The development and commercialization of the company's product candidates are subject to extensive regulatory review and approval processes by health authorities.
  • Clinical Trial Risks [high — operational]: The success of the company's product candidates relies on the outcomes of clinical trials, which may fail to demonstrate safety or efficacy.

Key Dates

  • 2024-03-21: 10-K Filing — Submission of the annual report for the fiscal year ended December 31, 2023.

Glossary

10-K
An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (Provides a detailed overview of Autolus Therapeutics' financial condition and business operations for the fiscal year 2023.)

Filing Stats: 4,509 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2024-03-21 16:55:59

Key Financial Figures

  • $0.000042 — ng one ordinary share, nominal value of $0.000042 per share AUTL The Nasdaq Global Selec
  • $2.38 — the closing sale price on that date of $2.38 per ADS. Shares held by each executive

Filing Documents

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 46 Item 1B. Unresolved Staff Comments 95 I tem 1C. C yber s ecurity 96 Item 2.

Properties

Properties 97 Item 3.

Legal Proceedings

Legal Proceedings 97 Item 4. Mine Safety Disclosures 98 P ART II 98 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 98 Item 6. [ Reserved ] 99 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 99 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 117 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 118 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures 118 Item 9A.

Controls and Procedures

Controls and Procedures 118 Item 9B. Other Information 119 Item 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections 120 P ART III 120 Item 10. Directors, Executive Officers and Corporate Governance 120 Item 11.

Executive Compensation

Executive Compensation 128 Item 12.

Security Ownership of Certain Beneficial Owner and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owner and Management and Related Stockholder Matters 135 Item 13. Certain Relationships and Related Transactions, and Director Independence 137 Item 14. Principal Accounting Fees and Services 139 P ART IV 139 Item 15. Exhibits, Financial Statement Schedules 139 Item 16. Form 10-K Summary 141

Signatures

Signatures 141 3 Tab le o f co ntents GENERAL INFORMATION All references in this Annual Report on Form 10-K ("the Annual Report") to "Autolus," the "Group," the "company," "we," "us" and "our" refer to Autolus Therapeutics plc and its consolidated subsidiaries, except where the context otherwise requires. "AUTOLUS" is our registered trademark. All other brand names and service marks, trademarks and other trade names appearing in this Annual Report are the property of their respective owners. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Exchange Act, that relate to future events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. In some cases, forward-looking statements are identified by the words "anticipate," "believe," "continue," "could," "estimate," "expect," "future," "goals," "intend," "likely," "may," "might," "ongoing," "objective," "plan," "potential," "predict," "project," "seek," "should," "strategy," "target," "will" and "would" or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements co

Business

Item 1. Business Business Overview We are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. We believe our programmed T cell therapies have the potential to be best-in-class and offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients. Our T cell programming technologies allow us to tailor our therapies to address the specific disease we are targeting and introduce new programming modules in to a patient's T cells to give those T cells improved properties to better recognize target cells and overcome fundamental disease defense mechanisms. Cancers in particular, thrive on their ability to fend off T cells by evading recognition by T cells and by establishing other defense mechanisms, such as checkpoint inhibition, and creating a hostile microenvironment. We believe our leadership in T cell programming technologies will provide us with a competitive advantage as we look to develop future generations of T cell therapies targeting both hematological cancers, solid tumors and autoimmune diseases, including potential products that could have a tolerability profile such to make them amenable to be used in outpatient settings.. Our current clinical-stage pipeline comprises five programs being developed in eight hematological and solid tumor indications and one autoimmune indication. 6 Tab le o f co ntents Our current clinical-stage programs are: Obe-cel (AUTO1): Obe-cel (obecabtagene autoleucel) is a CD19-targeting programmed T cell investigational therapy with a CD19 binder designed to improve the efficacy and safety profile

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.